Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Anlotinib in Advanced NSCLC
NCT07703228Phase 2Active, not recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate up to 2 years. Started Aug 2025; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07703228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703228.